Cardiac Sarcoidosis: Disease-Characteristics Research Report

Executive summary

Cardiac sarcoidosis (CS; MONDO:0001707) is an immune-mediated, non-necrotizing granulomatous myocarditis that may accompany systemic sarcoidosis or occur as apparently isolated cardiac disease. Active granulomatous inflammation and later replacement fibrosis injure the conduction system and myocardium, producing atrioventricular (AV) block, ventricular arrhythmias, heart failure, and sudden cardiac death. Clinical cardiac involvement is recognized in approximately 2–5% of sarcoidosis cases, whereas imaging and autopsy studies suggest much more frequent occult involvement. No single biomarker, gene, or test establishes the diagnosis; contemporary practice integrates clinical phenotype, extracardiac histology, cardiac magnetic resonance (CMR), fluorodeoxyglucose positron-emission tomography (FDG-PET), and selectively targeted endomyocardial biopsy (EMB). (sivalokanathan2024exploringtherole pages 5-7, sivalokanathan2024exploringtherole pages 1-2, trivieri2020challengesincardiac pages 1-3)

The evidence base remains limited. Glucocorticoids are first-line therapy, but randomized evidence defining dose, duration, mortality benefit, or optimal steroid-sparing treatment is lacking. The strongest observational evidence supports recovery of AV conduction and preservation of ventricular function. Recent research emphasizes multimodality imaging, macrophage-directed imaging, IL-1 and JAK inhibition, preclinical inflammatory biomarkers, and genetics-informed phenotype classification. (trivieri2020challengesincardiac pages 4-6, trivieri2020challengesincardiac pages 12-14, NCT06868381 chunk 1, NCT07159074 chunk 1, NCT06660732 chunk 1)

Table: This compact table summarizes the main knowledge-base domains for cardiac sarcoidosis, including disease definition, pathobiology, diagnostics, prognosis, treatment response, and ongoing trials. It is designed as a concise scaffold for a fuller cited report.

1. Disease information

Definition and scope

CS is best defined as granulomatous inflammation of the myocardium, with or without clinically evident extracardiac sarcoidosis. Histology shows compact, non-necrotizing granulomas containing macrophages/epithelioid histiocytes, multinucleated giant cells, and predominantly CD4-positive T lymphocytes. This finding is characteristic but not pathognomonic; infectious and other inflammatory causes must be excluded. A useful exact statement from a 2024 review is: “Sarcoidosis is a multifaceted and multisystemic inflammatory disorder, the etiology of which remains unknown.” [Sivalokanathan, June 2024; DOI URL: https://doi.org/10.3390/cardiogenetics14020009]. (sivalokanathan2024exploringtherole pages 5-7, sivalokanathan2024exploringtherole pages 1-2, trivieri2020challengesincardiac pages 1-3)

Identifiers and synonyms

• MONDO: MONDO:0001707, cardiac sarcoidosis. Open Targets recognizes this entity but returned no curated disease–target associations, consistent with the absence of an established single therapeutic target or causal gene. (OpenTargets Search: cardiac sarcoidosis)
• MeSH: Sarcoidosis and Heart Diseases are generally combined; a unique cardiac-sarcoidosis MeSH descriptor was not established in the retrieved evidence.
• ICD-10-CM: D86.85, sarcoid myocarditis, is the most specific commonly used code; coding systems may also use D86.9 plus a cardiac-manifestation code.
• ICD-11, OMIM, Orphanet: no confidently verified disease-specific identifier was recovered. CS is not an established Mendelian OMIM disorder.
• Synonyms: sarcoid myocarditis, myocardial sarcoidosis, cardiac involvement in sarcoidosis, isolated cardiac sarcoidosis, sarcoid cardiomyopathy.
• Data provenance: the report concerns aggregated disease-level evidence, not individual EHR records. Cohort statistics may nevertheless originate from registries, imaging databases, pathology series, or administrative health records.

2. Etiology, risk, and protective factors

Causal model

The cause is unknown and is probably multifactorial: genetically susceptible individuals encounter one or more environmental or microbial antigens, develop persistent antigen presentation and Th1-skewed cellular immunity, form granulomas, and subsequently develop myocardial injury and fibrosis. This is susceptibility rather than classical Mendelian causation. (sivalokanathan2024exploringtherole pages 5-7, trivieri2020challengesincardiac pages 1-3, trivieri2020challengesincardiac pages 4-6)

Genetic susceptibility

Familial clustering is reported in approximately 3.6–9.6% of sarcoidosis, monozygotic twins have markedly elevated risk, and first-degree relatives of affected Black patients have approximately threefold higher risk. A 2024 review cites an approximately 80-fold twin risk, although that estimate pertains to sarcoidosis broadly rather than specifically to cardiac involvement. HLA and non-HLA alleles influence susceptibility and phenotype; reported cardiac associations include HLA-DQB1*06:01, but replication and ancestry-specific interpretation are required. (sivalokanathan2024exploringtherole pages 5-7)

Recent systemic-sarcoidosis studies provide candidate phenotype modifiers rather than CS-causal genes. An ocular-cardio-cutaneous-CNS phenotype was associated with LOC102723568 and TLR3 variants; other extrapulmonary associations included CCL18, RAB23, and ZNF451. A December 2024 preprint found chronicity associations at rs3135356 (OR 3.13), rs2395162 (OR 2.34), and rs1049550 (OR 0.68), with gene-based signals at CLIC1 and ANXA11. These findings are not validated CS diagnostic variants. (zoppa2024phenotypesandserum pages 9-11, kullberg2024unravelinggeneticmysteries pages 1-5)

Knowledge-base conclusion: no established causal gene, pathogenic germline variant, somatic variant, chromosomal abnormality, inheritance pattern, penetrance estimate, carrier frequency, founder mutation, or clinically actionable modifier gene exists for CS. Accordingly, ClinVar-style pathogenic-variant classification, gnomAD carrier frequencies, cascade genetic testing, and genotype-directed treatment are not applicable at present. Open Targets likewise returned zero associated targets for MONDO:0001707. (OpenTargets Search: cardiac sarcoidosis)

Environment, occupation, lifestyle, and infection

Reported sarcoidosis associations include musty odors, pine pollen, insecticides, and occupational exposure to metals, talc, or silica. These are epidemiological signals, not proven CS-specific causes. Putative microbial antigens—particularly Cutibacterium acnes and mycobacterial antigens—remain hypotheses; sarcoidosis is not considered contagious, and no infectious agent fulfills causal criteria. Smoking, alcohol, diet, and exercise have no validated CS-specific causal or protective effect. (sivalokanathan2024exploringtherole pages 5-7)

Protective factors and gene–environment interaction

No reproducible genetic protective variant or environmental protective intervention has been established for CS. The leading interaction model is HLA-dependent antigen presentation after exposure, followed by persistent macrophage–T-cell activation. This model is biologically plausible but has not yielded a validated individual risk calculator.

3. Phenotypes

CS is predominantly adult-onset, often insidious, but may present abruptly with high-grade AV block, sustained ventricular tachycardia (VT), or cardiac arrest. Severity and progression are highly variable; silent inflammation, episodic activity, chronic scar, and progressive cardiomyopathy can coexist. (sivalokanathan2024exploringtherole pages 1-2, sivalokanathan2024exploringtherole pages 4-5)

Formal per-phenotype prevalence estimates are difficult to generalize because referral, diagnostic, and device cohorts differ markedly. Sarcoidosis overall can remit spontaneously, but scar-mediated CS may remain arrhythmogenic after inflammation resolves. A completed 130-participant study, NCT05145023, was designed to develop and validate a CS-specific health-related QoL instrument, reflecting a recognized gap in disease-specific patient-reported outcomes.

4. Genetic and molecular information

CS is polygenic/multifactorial, not a monogenic cardiomyopathy. There is therefore no recommended “CS gene panel.” In an apparent isolated inflammatory/arrhythmogenic cardiomyopathy, a hereditary cardiomyopathy panel or exome/genome sequencing may instead identify a phenocopy—such as desmosomal arrhythmogenic cardiomyopathy, LMNA-related cardiomyopathy, or other inherited disease—but does not confirm sarcoidosis.

Candidate pathways include HLA class II antigen presentation, TNF/NF-κB, interferon signaling, Toll-like receptor signaling, chemokine axes such as CXCL9/CXCL10–CXCR3, and possibly mTOR-related macrophage persistence. Systemic-sarcoidosis network analysis identified 493 viral-defense/innate-immunity genes and 684 genes related to noncoding-RNA processes; these remain research-level observations rather than clinical molecular diagnostics. (zoppa2024phenotypesandserum pages 9-11)

Epigenetic, cardiac single-cell, spatial-transcriptomic, proteomic, metabolomic, and lipidomic data remain sparse. Spatial transcriptomics and mass-spectrometry imaging are emerging methods for mapping sarcoid granulomas, but no clinically validated CS molecular signature has resulted. Absence of a curated Open Targets association further argues against assigning a single causal protein. (OpenTargets Search: cardiac sarcoidosis)

5. Environmental information

Organic and inorganic exposures may initiate disease in susceptible hosts, but no exposure is necessary or sufficient. Occupational histories should document metal work, mineral/silica or talc exposure, insecticides, mold/musty environments, and relevant infectious risks because these also inform the differential diagnosis. There is no evidence-based dietary or exercise intervention that prevents granuloma formation. Exercise prescriptions should instead be individualized after arrhythmia and ventricular-function assessment. (sivalokanathan2024exploringtherole pages 5-7)

Immunosuppressed patients require ordinary infection-risk mitigation, vaccination review, and latent tuberculosis/hepatitis screening before biologic therapy. These measures prevent treatment complications, not CS itself.

6. Mechanism and pathophysiology

Causal chain

1. Upstream susceptibility and trigger: HLA/non-HLA background plus unidentified inhaled, occupational, or microbial antigen.
2. Antigen presentation: recruited monocytes differentiate into macrophages/antigen-presenting cells and activate CD4-positive T cells.
3. Granuloma formation: Th1 cytokines—IL-2, TNF-α, and IFN-γ—maintain macrophage activation. Macrophages release IL-1, IL-6, IL-8, IL-12, IL-15, IL-18, and TNF-α. (trivieri2020challengesincardiac pages 4-6)
4. Active myocardial injury: patchy edema and inflammatory-cell infiltration injure cardiomyocytes and conduction tissue; glucose-avid immune cells produce focal FDG uptake.
5. Downstream remodeling: granulomas resolve, persist, or evolve into replacement fibrosis. Scar causes conduction slowing, re-entry VT, wall-motion abnormalities, reduced LVEF, and heart failure.
6. Clinical manifestations: AV block, VT/VF, syncope, heart failure, or sudden death. Continued arrhythmia after PET normalization can reflect fixed scar rather than active inflammation.

A possible Th1-to-Th2 transition may favor fibrosis in chronic disease. No protein misfolding, enzyme deficiency, ion-channel mutation, or primary metabolic block defines CS. Metabolic imaging instead exploits increased glucose consumption by activated inflammatory cells. (trivieri2020challengesincardiac pages 4-6)

Suggested GO biological-process terms: GO:0006954 inflammatory response; GO:0071222 cellular response to lipopolysaccharide/antigenic stimulus where contextually justified; GO:0001816 cytokine production; GO:0042110 T-cell activation; GO:0006955 immune response; GO:0002376 immune system process; GO:0001525 angiogenesis; GO:0042060 wound healing; GO:0030198 extracellular-matrix organization; GO:0062023 collagen-containing extracellular matrix.

Suggested Cell Ontology terms: CL:0000235 macrophage; CL:0000863 inflammatory macrophage; CL:0000624 CD4-positive alpha-beta T cell; CL:0000813 memory T cell; CL:0000576 monocyte; CL:0000182 hepatocyte-like “epithelioid” is inappropriate—use macrophage lineage plus pathology annotation; CL:0000746 cardiac muscle cell; CL:0000057 fibroblast.

7. Anatomical structures affected

• Primary organ: heart, particularly patchy ventricular myocardium and the conduction system. Suggested terms: UBERON:0000948 heart, UBERON:0002349 myocardium, UBERON:0002084 cardiac muscle tissue, UBERON:0002405 cardiac ventricle.
• Common sites: basal interventricular septum, left-ventricular subepicardial/mid-wall myocardium, papillary muscles, and right ventricle. Distribution is often multifocal and asymmetric rather than lateralized.
• Cells/tissues: cardiomyocytes are injured secondarily; macrophages, giant cells, lymphocytes, fibroblasts, and collagenous scar dominate lesions.
• Subcellular level: no disease-specific organelle lesion is established. Nuclear transcriptional programs, macrophage lysosomal/phagocytic compartments, mitochondria under inflammatory stress, and extracellular matrix are relevant but nonspecific.
• Secondary organs: lungs and thoracic lymph nodes are most frequent systemic sites; skin, eyes, nervous system, liver, and other organs may provide safer biopsy targets. More than 90% of systemic sarcoidosis patients may have an abnormal chest radiograph, with bilateral hilar adenopathy in 50–85% and parenchymal opacity in 20–65%. (sivalokanathan2024exploringtherole pages 1-2)

8. Temporal development

Typical onset is adult, commonly between 25 and 45 years for sarcoidosis broadly, although later presentation occurs. Disease may be acute—e.g., sudden AV block or VT—or chronic and insidious. Systemic sarcoidosis is often categorized as acute (≤2 years) or chronic/persistent (approximately ≥3–5 years), but this staging does not map cleanly onto cardiac activity. (sivalokanathan2024exploringtherole pages 4-5)

A practical cardiac sequence is: subclinical inflammation → clinically active granulomatous myocarditis → mixed inflammation and fibrosis → scar-dominant cardiomyopathy. Activity fluctuates, and relapse may follow immunosuppression withdrawal. Early immunosuppression before marked LVEF decline appears more effective; treatment within six months was associated with LVEF improvement, whereas delay beyond six months predicted poorer response in observational data. (trivieri2020challengesincardiac pages 12-14)

For sarcoidosis overall, 30–50% or more may remit spontaneously, but cardiac involvement is not safely managed by extrapolating pulmonary remission rates. A 2024 Swedish nested case–control study found 44 inflammatory plasma proteins elevated before diagnosis among 152 cases and 341 controls; mean lead time was 13.4 years, and 27 remained associated ≥10 years before diagnosis. This supports a preclinical inflammatory phase, although it was not CS-specific. [Arkema et al., September 2024; https://doi.org/10.1183/13993003.00277-2024].

9. Inheritance and population

Sarcoidosis prevalence estimates vary from approximately 1–40 per 100,000 globally to 141–160 per 100,000 in selected northern-latitude populations; incidence estimates span approximately 1–36 per 100,000/year. Clinical CS occurs in about 2–5% of sarcoidosis, whereas imaging or autopsy detects myocardial involvement in approximately 20–25% and, in selected postmortem series, 25–58%. These ranges must not be conflated: they reflect different case definitions and ascertainment. (sivalokanathan2024exploringtherole pages 5-7, sivalokanathan2024exploringtherole pages 1-2, trivieri2020challengesincardiac pages 1-3, sivalokanathan2024exploringtherole pages 4-5, zoppa2024phenotypesandserum pages 1-2)

Black/African-American and Northern European populations have a higher systemic burden; African-American patients may present roughly a decade earlier and with more severe disease. Japanese cohorts have historically shown a disproportionate cardiac contribution to sarcoidosis mortality. Sex estimates vary by cohort, but systemic sarcoidosis generally shows modest female predominance, approximately 1.2–1.5:1 in a recent review. (trivieri2020challengesincardiac pages 1-3, zoppa2024phenotypesandserum pages 1-2)

A 2024 Finnish nationwide study documented increasing recognized CS incidence over 30 years, likely reflecting heightened awareness and advanced imaging as well as possible true change. Precise cohort estimates were not recoverable from the available excerpt and should not be inferred. [Pöyhönen et al., August 2024; https://doi.org/10.1016/j.jacadv.2024.101102]. (poyhonen202430yeartrendsin pages 11-11)

Classical inheritance concepts—autosomal dominant/recessive transmission, penetrance, anticipation, germline mosaicism, carrier frequency, and consanguinity—are not applicable.

10. Diagnostics

Diagnostic criteria

Three major frameworks coexist:

1. 2014 Heart Rhythm Society (HRS): either myocardial histology or a clinical pathway requiring histologically proven extracardiac sarcoidosis plus compatible cardiac findings after exclusion of alternatives.
2. WASOG: grades probability of organ involvement and emphasizes granulomatous evidence.
3. Japanese Circulation Society/JMHW revisions: major/minor criteria, with a pathway for isolated CS and greater reliance on CMR and FDG-PET.

HRS and WASOG show relatively high concordance, whereas agreement with JCS is lower. Thus, a knowledge-base entry should preserve the criterion set and year used rather than treating all “clinical CS” labels as equivalent. (nagai2026thediagnosisand pages 4-6, trivieri2020challengesincardiac pages 9-11)

Recommended evaluation

• History/examination: palpitations, syncope, exertional dyspnea, chest pain, family history, extracardiac symptoms, exposure/infection history.
• ECG and ambulatory monitoring: AV block, bundle-branch block, ventricular ectopy, nonsustained/sustained VT, pathological Q waves, or repolarization abnormalities.
• Echocardiography: LVEF, regional wall motion, septal thinning/thickening, aneurysm, RV function, and strain. A normal echocardiogram does not exclude CS.
• CMR: LGE identifies necrosis/fibrosis, often in nonischemic subepicardial or mid-myocardial patterns; T1/T2 mapping can support active injury. One recent review reports sensitivity 91–99% and specificity 98–100%, whereas screening studies report sensitivity 75–100% and specificity 76–78%, illustrating strong spectrum and reference-standard effects. (nagai2026thediagnosisand pages 4-6, trivieri2020challengesincardiac pages 9-11)
• FDG-PET plus perfusion imaging: identifies metabolically active inflammation and helps monitor treatment. Reported sensitivity is 71–91% and specificity 74–89%; a commonly cited pooled benchmark is approximately 89%/78%. High-fat/low-carbohydrate preparation and prolonged fasting are essential to suppress physiological myocardial uptake. (nagai2026thediagnosisand pages 4-6, trivieri2020challengesincardiac pages 9-11)
• Biopsy: extracardiac tissue is preferred when available. EMB is highly specific but has only approximately 20–30% sensitivity or ~25% unguided yield because lesions are patchy. Imaging- or voltage-guided biopsy may raise yield toward 50%. A negative EMB does not exclude CS. (nagai2026thediagnosisand pages 4-6, trivieri2020challengesincardiac pages 9-11)

Biomarkers

Troponin and BNP/NT-proBNP measure myocardial injury and hemodynamic stress; elevated high-sensitivity troponin correlates with active FDG uptake. ACE, soluble IL-2 receptor, CRP/ESR, calcium, liver tests, and blood counts characterize systemic disease or treatment safety but are insufficiently specific for diagnosis. No validated serum biomarker independently establishes CS. miR-126 and miR-223 have been reported higher in CS than controls but remain investigational. (trivieri2020challengesincardiac pages 4-6)

Systemic-sarcoidosis estimates include sIL-2R thresholds of 4,700 U/L for chronicity prediction and 482 U/mL with 84.2% sensitivity/53.6% specificity in a separate context; these assay- and cohort-specific cutoffs should not be adopted as CS diagnostic thresholds. (zoppa2024phenotypesandserum pages 9-11)

Differential diagnosis

Key exclusions are ischemic cardiomyopathy, lymphocytic/viral myocarditis, giant-cell myocarditis, arrhythmogenic cardiomyopathy, LMNA and other genetic cardiomyopathies, hypertrophic or dilated cardiomyopathy, cardiac amyloidosis, Chagas disease where epidemiologically relevant, tuberculosis/fungal granulomatous disease, hypersensitivity myocarditis, and cardiac lymphoma. Coronary-territory scar favors ischemia; diffuse subendocardial LGE favors amyloid; desmosomal variants and characteristic structural patterns favor inherited arrhythmogenic cardiomyopathy. Histology and microbiology are essential when infection or giant-cell myocarditis is possible.

Screening and genetic testing

Patients with extracardiac sarcoidosis should undergo symptom review and ECG; many centers add echocardiography. Abnormal symptoms, ECG, Holter, or echo warrant CMR and/or FDG-PET. Universal advanced-imaging screening of all asymptomatic patients remains controversial. No newborn, population, carrier, prenatal, or cascade-genetic screening is recommended. WES/WGS, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing have no routine role unless evaluating an alternative inherited cardiomyopathy.

11. Outcome and prognosis

Major adverse outcomes are sustained VT/VF, complete heart block, progressive biventricular failure, device shocks, transplantation, and sudden death. Morbidity includes exercise limitation, fatigue, anxiety over arrhythmias/device therapy, inability to drive or work, and cumulative immunosuppressive toxicity. Heart failure and ventricular arrhythmias account for most CS morbidity and mortality. (trivieri2020challengesincardiac pages 1-3)

Strong adverse markers include reduced LVEF or RV function, extensive CMR LGE, RV involvement, active FDG uptake, perfusion defects, prior VT, syncope, and high-grade AV block. Combined perfusion defect plus abnormal FDG uptake was associated with approximately fourfold higher annual VT/death rates, and RV FDG uptake with approximately fivefold higher event rates. CMR scar burden may outperform PET activity for long-term major-event prediction because fixed fibrosis remains arrhythmogenic after inflammation subsides. (trivieri2020challengesincardiac pages 9-11)

Selected reviews cite sudden-death rates up to 14%, but universal 5- and 10-year survival figures cannot be given reliably because outcomes vary by era, diagnostic criteria, phenotype, and referral setting. Modern imaging, ICD use, immunosuppression, and heart-failure treatment have improved outcomes, yet robust treatment-versus-no-treatment life-expectancy estimates are unavailable. (sivalokanathan2024exploringtherole pages 5-7)

12. Treatment

Immunosuppression

Glucocorticoids are first-line for clinically active CS. Prednisone 30–40 mg/day is a commonly proposed initial regimen, followed by gradual taper guided by symptoms, ventricular function, arrhythmias, biomarkers, and PET activity; no universally validated dose or duration exists. Earlier treatment, before advanced ventricular dysfunction and fibrosis, appears more effective. (trivieri2020challengesincardiac pages 12-14)

Steroid-sparing agents include methotrexate, azathioprine, mycophenolate mofetil, and leflunomide; cyclophosphamide is reserved for selected refractory severe disease. TNF-α inhibitors—particularly infliximab—are used in refractory disease after infection screening and careful heart-failure assessment. Evidence is predominantly retrospective and should not be interpreted as regulatory approval specifically for CS.

A systematic review of 34 reports encompassing 1,297 patients found no randomized trials and only two good-quality studies. Among 178 treated patients with AV conduction disease, 76 (42.7%) improved, versus 0 of 21 untreated patients. Treatment was associated with prevention of LVEF deterioration, but evidence was inadequate to conclude a ventricular-arrhythmia or mortality benefit. The authors’ exact conclusion was: “The data quality is too limited to draw conclusions for ventricular arrhythmias and mortality.” [Fazelpour et al., September 2021; https://doi.org/10.1161/JAHA.121.021183]. Combination immunosuppression reduced relapse from 46% to 17% in one observational comparison, and prednisone plus methotrexate showed persistent five-year benefit over prednisone alone in another. (trivieri2020challengesincardiac pages 12-14)

Cardiac and interventional management

• Treat HFrEF with guideline-directed therapy as tolerated.
• Pacemaker implantation is indicated for clinically important bradycardia/AV block, but an ICD is often favored because future VT/VF risk may persist even if conduction recovers.
• Antiarrhythmics, commonly amiodarone or sotalol, may be used with specialist oversight.
• Catheter ablation treats recurrent scar-mediated VT but recurrence is common when inflammation remains active or the substrate is extensive.
• Cardiac resynchronization is appropriate under standard criteria.
• Mechanical circulatory support and heart transplantation are options for refractory end-stage disease; recurrence in the graft is reported but uncommon.

Suggested NCIT intervention concepts include Prednisone, Methotrexate, Azathioprine, Mycophenolate Mofetil, Infliximab, Anakinra, Rilonacept, Baricitinib, Implantable Cardioverter-Defibrillator, Cardiac Pacemaker, Catheter Ablation, Cardiac Resynchronization Therapy, and Heart Transplantation.

Experimental and recent trials

• REPAIR-CS, NCT06660732: recruiting Phase II randomized trial, 60 participants; rilonacept 320-mg loading dose then 160 mg weekly added to standard treatment. Primary endpoint is change in FDG-positive myocardial segments through 24 weeks; started March 5, 2025, with no posted results. (NCT06660732 chunk 1)
• NCT06868381: Phase IIa open-label baricitinib 4 mg/day, planned enrollment 10, not yet recruiting; estimated start April 1, 2026. Primary endpoint is resolution of cardiac FDG uptake; QoL and ACE, hs-troponin I, NT-proBNP, ESR, and CRP are secondary measures. No results posted. (NCT06868381 chunk 1)
• MAGiC-ART, NCT04017936: completed 17-participant pilot of anakinra/IL-1 blockade; results were published in May 2023, but the retrieved record did not provide sufficient quantitative efficacy data for reliable extraction. (NCT04017936 chunk 2)
• NCT07159074: recruiting Phase II diagnostic study of Tc-99m tilmanocept SPECT/CT, 15 participants, correlating macrophage-directed uptake with FDG-PET and CMR; started September 17, 2025. No results posted. (NCT07159074 chunk 1)
• Other registered research includes 64Cu-DOTATATE macrophage PET/CT (NCT06131112; recruiting, n=76), PET/MRI prognosis (NCT05954507; recruiting, n=180), SGLT1/2-assisted myocardial glucose suppression (NCT06510894; recruiting, n=40), diagnostic-criteria validation (NCT04737317; recruiting, n=100), and biomaterial collection (NCT05793398; planned, n=100).

No gene, cell, RNA, or CRISPR therapy is established or in routine clinical development for CS. Pharmacogenomic dosing is not standard; ordinary drug-specific safety monitoring remains essential.

13. Prevention

Primary prevention: none is proven because the causal antigen is unknown. There is no CS vaccine, prophylactic drug, validated exposure-avoidance program, or genetic reproductive intervention.

Secondary prevention: recognize occult cardiac disease in systemic sarcoidosis through symptom review, ECG, and selected ambulatory monitoring/echocardiography, followed by CMR/PET when abnormalities or high clinical suspicion exist. Evaluate unexplained high-grade AV block or VT for CS before labeling it idiopathic.

Tertiary prevention: suppress active inflammation; monitor ventricular function, rhythm, and PET activity; use ICD/pacing where indicated; apply guideline-directed heart-failure therapy; manage osteoporosis, diabetes, infection, and other immunosuppression toxicities; and provide vaccination and rehabilitation advice. Genetic counseling may explain familial aggregation and multifactorial risk, but predictive family genetic testing is not available.

14. Other species and natural disease

Naturally occurring systemic granulomatous disease and granulomatous myocarditis occur in animals, but a well-validated spontaneous veterinary analogue of human CS—with comparable epidemiology, genetics, and diagnostic criteria—was not identified. Consequently, no reliable NCBI Taxon/VBO breed association, orthologous causal gene, zoonotic transmission pathway, or cross-species carrier state can be assigned. Human sarcoidosis is not considered zoonotic or transmissible.

15. Model organisms and experimental systems

No single model reproduces the full human syndrome of patchy cardiac granulomas, relapsing inflammation, fibrosis, conduction block, and VT. Experimental sarcoidosis models include antigen- or C. acnes-induced murine granulomas, mycobacterial-protein models, macrophage/T-cell cultures, and human tissue imaging. Most primarily model pulmonary granuloma biology rather than cardiac electrophysiology. Their value lies in studying antigen presentation, macrophage persistence, TNF/IFN signaling, and fibrosis; their limitations are uncertain initiating antigen, strain dependence, noncardiac predominance, and incomplete chronic scar/arrhythmia phenotypes.

Human explanted hearts, EMB material, extracardiac granulomas, and induced-pluripotent-stem-cell cardiomyocytes exposed to inflammatory mediators can address cell injury but do not recreate multicellular granuloma architecture. Emerging spatial transcriptomics and matrix-assisted laser-desorption/ionization imaging can map cell neighborhoods and molecular gradients in human granulomas, but remain discovery tools rather than validated models or diagnostics.

Evidence appraisal and knowledge-base cautions

1. Human clinical evidence: strongest for imaging diagnosis/risk stratification, device-based prevention, and observational improvement in AV conduction/LVEF with immunosuppression.
2. Mechanistic evidence: principally extrapolated from systemic sarcoidosis, pathology, and immune profiling; the initiating antigen remains unknown.
3. Genetic evidence: association-level and phenotype-modifying, not Mendelian or clinically diagnostic.
4. Model-organism evidence: sparse for cardiac-specific disease and weaker than human clinicopathologic evidence.
5. Direct-quote limitation: exact short quotations were included only where supported by retrieved text. PMID values were not consistently available in the retrieved records; DOI URLs and publication dates are therefore supplied rather than inventing PMIDs.
6. Critical implementation rule: retain the diagnostic framework, imaging-preparation protocol, ancestry, ascertainment method, and evidence type with every knowledge-base assertion. Clinical, autopsy, and imaging prevalence estimates are not interchangeable.

References

1. (sivalokanathan2024exploringtherole pages 5-7): Sanjay Sivalokanathan. Exploring the role of genetics in sarcoidosis and its impact on the development of cardiac sarcoidosis. Cardiogenetics, 14:106-121, Jun 2024. URL: https://doi.org/10.3390/cardiogenetics14020009, doi:10.3390/cardiogenetics14020009. This article has 5 citations.

2. (sivalokanathan2024exploringtherole pages 1-2): Sanjay Sivalokanathan. Exploring the role of genetics in sarcoidosis and its impact on the development of cardiac sarcoidosis. Cardiogenetics, 14:106-121, Jun 2024. URL: https://doi.org/10.3390/cardiogenetics14020009, doi:10.3390/cardiogenetics14020009. This article has 5 citations.

3. (trivieri2020challengesincardiac pages 1-3): Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C. Kovacic, Robert Baughman, Zahi A. Fayad, and Marc A. Judson. Challenges in cardiac and pulmonary sarcoidosis: jacc state-of-the-art review. Journal of the American College of Cardiology, 76 16:1878-1901, Oct 2020. URL: https://doi.org/10.1016/j.jacc.2020.08.042, doi:10.1016/j.jacc.2020.08.042. This article has 254 citations and is from a highest quality peer-reviewed journal.

4. (trivieri2020challengesincardiac pages 4-6): Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C. Kovacic, Robert Baughman, Zahi A. Fayad, and Marc A. Judson. Challenges in cardiac and pulmonary sarcoidosis: jacc state-of-the-art review. Journal of the American College of Cardiology, 76 16:1878-1901, Oct 2020. URL: https://doi.org/10.1016/j.jacc.2020.08.042, doi:10.1016/j.jacc.2020.08.042. This article has 254 citations and is from a highest quality peer-reviewed journal.

5. (trivieri2020challengesincardiac pages 12-14): Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C. Kovacic, Robert Baughman, Zahi A. Fayad, and Marc A. Judson. Challenges in cardiac and pulmonary sarcoidosis: jacc state-of-the-art review. Journal of the American College of Cardiology, 76 16:1878-1901, Oct 2020. URL: https://doi.org/10.1016/j.jacc.2020.08.042, doi:10.1016/j.jacc.2020.08.042. This article has 254 citations and is from a highest quality peer-reviewed journal.

6. (NCT06868381 chunk 1): Matthew C. Baker. A Trial of Baricitinib in Patients With Cardiac Sarcoidosis. Stanford University. 2026. ClinicalTrials.gov Identifier: NCT06868381

7. (NCT07159074 chunk 1): Repurposing Tilmanocept for Cardiac Sarcoidosis. Duke University. 2025. ClinicalTrials.gov Identifier: NCT07159074

8. (NCT06660732 chunk 1): Andrew N Rosenbaum. Rilonacept in Subjects With Cardiac Sarcoidosis. Mayo Clinic. 2025. ClinicalTrials.gov Identifier: NCT06660732

9. (OpenTargets Search: cardiac sarcoidosis): Open Targets Query (cardiac sarcoidosis, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

10. (sivalokanathan2024exploringtherole pages 4-5): Sanjay Sivalokanathan. Exploring the role of genetics in sarcoidosis and its impact on the development of cardiac sarcoidosis. Cardiogenetics, 14:106-121, Jun 2024. URL: https://doi.org/10.3390/cardiogenetics14020009, doi:10.3390/cardiogenetics14020009. This article has 5 citations.

11. (poyhonen202430yeartrendsin pages 11-11): Pauli Pöyhönen, Jukka Lehtonen, Diana Velikanova, Piia Simonen, Valtteri Uusitalo, Henriikka Mälkönen, Hanna-Kaisa Nordenswan, Tapani Vihinen, Kari Kaikkonen, Petri Haataja, Tuomas Kerola, Tuomas T. Rissanen, Ville Vepsäläinen, Aleksi Alatalo, Päivi Pietilä-Effati, and Markku Kupari. 30-year trends in the incidence, characteristics, and outcome of cardiac sarcoidosis in a nationwide cohort. Aug 2024. URL: https://doi.org/10.1016/j.jacadv.2024.101102, doi:10.1016/j.jacadv.2024.101102. This article has 13 citations.

12. (zoppa2024phenotypesandserum pages 9-11): Matteo Della Zoppa, Francesco Rocco Bertuccio, Ilaria Campo, Fady Tousa, Mariachiara Crescenzi, Sara Lettieri, Francesca Mariani, Angelo Guido Corsico, Davide Piloni, and Giulia Maria Stella. Phenotypes and serum biomarkers in sarcoidosis. Diagnostics, 14:709, Mar 2024. URL: https://doi.org/10.3390/diagnostics14070709, doi:10.3390/diagnostics14070709. This article has 18 citations.

13. (kullberg2024unravelinggeneticmysteries pages 1-5): Susanna Kullberg, Pernilla Darlington, David Ellinghaus, Antje Prasse, Tomoko Iseda, Olga Chuquimia, Anders Eklund, Stefan Schreiber, Joachim Müller-Quernheim, Ingrid Kockum, Åsa Wheelock, Leonid Padyukov, Mehdi S. Mirsaeidi, Paolo Spagnolo, and Natalia V. Rivera. Unraveling genetic mysteries: phenotype-shaping profiles in chronic sarcoidosis. MedRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.29.24319750, doi:10.1101/2024.12.29.24319750. This article has 2 citations.

14. (trivieri2020challengesincardiac pages 20-21): Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C. Kovacic, Robert Baughman, Zahi A. Fayad, and Marc A. Judson. Challenges in cardiac and pulmonary sarcoidosis: jacc state-of-the-art review. Journal of the American College of Cardiology, 76 16:1878-1901, Oct 2020. URL: https://doi.org/10.1016/j.jacc.2020.08.042, doi:10.1016/j.jacc.2020.08.042. This article has 254 citations and is from a highest quality peer-reviewed journal.

15. (trivieri2020challengesincardiac pages 9-11): Maria Giovanna Trivieri, Paolo Spagnolo, David Birnie, Peter Liu, Wonder Drake, Jason C. Kovacic, Robert Baughman, Zahi A. Fayad, and Marc A. Judson. Challenges in cardiac and pulmonary sarcoidosis: jacc state-of-the-art review. Journal of the American College of Cardiology, 76 16:1878-1901, Oct 2020. URL: https://doi.org/10.1016/j.jacc.2020.08.042, doi:10.1016/j.jacc.2020.08.042. This article has 254 citations and is from a highest quality peer-reviewed journal.

16. (nagai2026thediagnosisand pages 4-6): Toshiyuki Nagai, Toshifumi Tamura, and Toshihisa Anzai. The diagnosis and management of cardiac sarcoidosis. Internal Medicine, Jan 2026. URL: https://doi.org/10.2169/internalmedicine.7161-26, doi:10.2169/internalmedicine.7161-26. This article has 2 citations and is from a peer-reviewed journal.

17. (NCT04017936 chunk 2): Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis. Virginia Commonwealth University. 2020. ClinicalTrials.gov Identifier: NCT04017936

18. (zoppa2024phenotypesandserum pages 1-2): Matteo Della Zoppa, Francesco Rocco Bertuccio, Ilaria Campo, Fady Tousa, Mariachiara Crescenzi, Sara Lettieri, Francesca Mariani, Angelo Guido Corsico, Davide Piloni, and Giulia Maria Stella. Phenotypes and serum biomarkers in sarcoidosis. Diagnostics, 14:709, Mar 2024. URL: https://doi.org/10.3390/diagnostics14070709, doi:10.3390/diagnostics14070709. This article has 18 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.